Fig. 3

ZEB1 promotes the transcription of POLDIP2. A The intersection of top 50 downstream targets of ZEB1 in the hTFtarget database and significantly differentially expressed genes screened in the GSE56815 dataset. B Detection of expression changes of six intersecting genes in bone tissues of rats overexpressing ZEB1. C Conserved binding sites for ZEB1 predicted using JASPAR and potential binding sites of ZEB1 to POLDIP2 promoter. D POLDIP2 expression in the blood of normal controls and OP patients (n = 40). E mRNA expression of POLDIP2 in bone tissues of sham- and OVX-treated rats by RT-qPCR. F mRNA expression of NFATC and CTSK in RAW264.7 cells infected with oe-NC or oe-ZEB1 after RANKL treatment by RT-qPCR. G Detection of mRNA expression of ZEB1 and POLDIP2 in RAW264.7 cells in response to oe-NC or oe-ZEB1 by RT-qPCR. H The enrichment ability of Anti-ZEB1 on POLDIP2 promoter in RAW264.7 cells in response to oe-NC or oe-ZEB1 by ChIP-qPCR. I Promoter luciferase activity of POLDIP2 examined in RAW264.7 cells in response to oe-NC or oe-ZEB1 using dual-luciferase assay. All data are represented as mean ± SD (n = 6 for rats in each group). Each experiment was performed three times independently. *p < 0.05, **p < 0.01, ***p < 0.001. Differences are tested using two-way ANOVA with Tukey’s post hoc test (F, G) and unpaired t-test (D, E, H, I)